Biological Agents Could Correct the Immune System Imbalance in MG, Study Suggests
Biological agents that target inflammation-generating immune cells and signaling molecules could be used to treat myasthenia gravis, French researchers report.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Biological agents that target inflammation-generating immune cells and signaling molecules could be used to treat myasthenia gravis, French researchers report.
Researchers have found that the long-term use of the immunosuppressive drug Prograf (tacrolimus) may contribute to the development of…
Higher amounts of anti-acetylcholine receptor (AchR) antibodies in the blood before surgically removing the thymus could be a good predictor…
A recent study by researchers from Yale University furthers understanding about why certain myasthenia gravis (MG) patients who were treated…
Vaccination for protection against tetanus is safe and does not aggravate any clinical or immunological features of myasthenia gravis, according…
Alteration of eye movement due to muscle weakness is not uncommon among patients with myasthenia gravis (MG). But now researchers…
The European Commission (EC) has approved Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in…
Heavier myasthenia gravis patients are at higher risk of having respiratory failure or other complications after their thymus is removed,…
ALS and myasthenia gravis have features in common, including an underlying immunological mechanism and alterations in communication junctions between muscle and…
Get regular updates to your inbox.